Xspray Pharma Past Earnings Performance

Past criteria checks 0/6

Xspray Pharma's earnings have been declining at an average annual rate of -36.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 109.2% per year.

Key information

-36.1%

Earnings growth rate

-22.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate109.2%
Return on equity-44.1%
Net Marginn/a
Next Earnings Update12 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Xspray Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:6XP Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-25817882
30 Jun 240-21519252
31 Mar 240-21319546
31 Dec 230-18017040
30 Sep 230-18016445
30 Jun 230-17012941
31 Mar 230-14811534
31 Dec 220-13211022
30 Sep 220-1289038
30 Jun 220-1147638
31 Mar 220-1026339
31 Dec 210-975839
30 Sep 210-60537
30 Jun 210-57517
31 Mar 210-56517
31 Dec 200-52477
30 Sep 200-56516
30 Jun 200-55496
31 Mar 200-49445
31 Dec 190-46423
30 Sep 19-22-412511
30 Jun 19-14-34229
31 Mar 19-6-30207
31 Dec 180-23176
30 Sep 1831-17230
30 Jun 1828-16220
31 Mar 1829-8190
31 Dec 170-14114
30 Sep 17351150
30 Jun 1730-3140
31 Mar 1721-7120
31 Dec 1621-4110
31 Dec 155-12110

Quality Earnings: 6XP is currently unprofitable.

Growing Profit Margin: 6XP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6XP is unprofitable, and losses have increased over the past 5 years at a rate of 36.1% per year.

Accelerating Growth: Unable to compare 6XP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6XP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 6XP has a negative Return on Equity (-44.07%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies